ERBB2 and breast cancer: Taken together, our results indicate the existence of Mcl-1-dependent survival pathways in Her2-positive BC cells, which are independent of the Mcl-1–Her2 axis; and support the therapeutic benefit of combining Her2 and Mcl-1 inhibitors.